Acquired Immunodeficiency Syndrome: all 3,037 studies

Page 8 of 31. Open to participants first (307), then studies with results posted, then the rest; newest registration first within each.

• Safety and Efficacy of (α1Proteinase Inhibitor, α1PI) in HIV DiseaseTerminatedNCT01731691Phase 2/3Results posted
• China Adherence Through Technology StudyCompletedNCT01722552Not applicableResults posted
• Comparison of Two Intrauterine Devices (IUDs) Among Cape Town HIV-positive WomenCompletedNCT01721798Not applicableResults posted
• CARE Corrections: Technology for Jail HIV/HCV Testing, Linkage, and Care (TLC)CompletedNCT01721226Not applicableResults posted
• Pharmacokinetics, Safety, and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in AdolescentsCompletedNCT01721109Phase 2/3Results posted
• Varenicline for Nicotine Dependence Among Those With HIV/AIDSCompletedNCT01710137Phase 3Results posted
• Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive WomenCompletedNCT01705574Phase 3Results posted
• Immunogenicity of Fluzone High Dose in Immunocompromised Children and Young AdultsCompletedNCT01685372Phase 2Results posted
• The Effect of Protease Inhibitors on the Pharmacokinetics of Oral Norethindrone ContraceptionCompletedNCT01667978Not applicableResults posted
• Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected AdultsCompletedNCT01667731Phase 3Results posted
• Real-life Effectiveness of the Kaletra Adherence Support Assistance (KASA) ProgramCompletedNCT01662336Results posted
• Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus RilpivirineCompletedNCT01641809Phase 2Results posted
• Development of Method of Fructose Identification in Urine to Detect the Viral InfectionCompletedNCT01638312Results posted
• Study to Optimize the Quality of Samples for Cell-mediated Immunity (CMI) in ART-naïve HIV-1-infected SubjectsCompletedNCT01610427Not applicableResults posted
• Cisplatin and Radiation Therapy in Treating Patients With HIV-Associated Locally Advanced Cervical CancerCompletedNCT01590017Phase 2Results posted
• D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive AdultsCompletedNCT01565850Phase 2Results posted
• HIV, Buprenorphine, and the Criminal Justice SystemCompletedNCT01550341Not applicableResults posted
• Intervention to Retain HIV-positive Patients in Medical CareCompletedNCT01537367Not applicableResults posted
• Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Raltegravir Plus Emtricitabine/Tenofovir DF Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected PatientsCompletedNCT01533259Phase 3Results posted
• Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)CompletedNCT01516970Phase 3Results posted
• American Ginseng to Improve HIV-Associated Fatigue: A Randomized, Placebo-Controlled, Parallel Design, Multiple-Dose Clinical TrialCompletedNCT01500096Phase 2Results posted
• A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in the Central Nervous System in HIV-1 Infected ART-naive SubjectsCompletedNCT01499199Phase 3Results posted
• Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Infected, Antiretroviral Treatment-Naive AdultsCompletedNCT01497899Phase 2Results posted
• Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected PatientsCompletedNCT01495702Phase 3Results posted
• Men Together Making a Difference: Reducing HIV/STD Risk Behavior Among South African MenCompletedNCT01490359Not applicableResults posted
• A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1CompletedNCT01479868Phase 3Results posted
• Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected PatientsCompletedNCT01475838Phase 3Results posted
• Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive SubjectsCompletedNCT01449929Phase 3Results posted
• A Study of the Neurological Effects of Adding Maraviroc to HAART Regimen in Patients With HIV (HANDmac)CompletedNCT01449006Phase 4Results posted
• A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current TreatmentCompletedNCT01448707Phase 3Results posted
• A Study of the Neurological Effects of Adding Raltegravir to HAART Regimen in Patients With HIVTerminatedNCT01448486Phase 4Results posted
• Boceprevir Drug Combination for Hepatitis C Treatment in People With and Without HIVTerminatedNCT01443923Phase 4Results posted
• Tocilizumab for KSHV-Associated Multicentric Castleman DiseaseCompletedNCT01441063Phase 2Results posted
• Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected AdultsCompletedNCT01440569Phase 3Results posted
• Lower Extremity Splinting to Manage Pain and Sleep Disturbances Associated With HIV/AIDS Related Peripheral NeuropathyCompletedNCT01419314Not applicableResults posted
• Home Assessment and Initiation of Antiretroviral Therapy for HIV in MalawiCompletedNCT01414413Not applicableResults posted
• Depression and ART Adherence in HIV+ LatinosCompletedNCT01411839Not applicableResults posted
• Eplerenone in HIV Associated Abdominal Fat AccumulationCompletedNCT01405456Not applicableResults posted
• A Study to Compare Brachial Artery Reactivity and Cardiovascular Risk of a Treatment Simplification by Darunavir/Ritonavir (DRV/r) 800/100 mg Versus a Triple Combination Therapy Containing DRV/r in HIV-1 Infected PatientsCompletedNCT01391013Phase 2Results posted
• HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) InfectionsCompletedNCT01384734Phase 2Results posted
• Treatment Perception of QD (Once a Day) Dosed Kaletra (Tablets)CompletedNCT01383005Results posted
• Safety and Tolerability of Crofelemer for HIV-Associated DiarrheaCompletedNCT01374490Phase 3Results posted
• Therapy to Elevate CD4 Counts in HIV-1 DiseaseCompletedNCT01370018Phase 2/3Results posted
• Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal ImpairmentCompletedNCT01363011Phase 3Results posted
• Prophylaxis of Visceral Leishmaniasis Relapses in HIV Co-infected Patients With Pentamidine: a Cohort StudyCompletedNCT01360762Phase 3Results posted
• Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With CCR5 Tropic HIV 1TerminatedNCT01345630Phase 3Results posted
• HIV Cohort Study At Johns Hopkins University, University of North Carolina at Chapel Hill and Vanderbilt UniversityCompletedNCT01339416Results posted
• Kaiser Permanente HIV Cohort StudyCompletedNCT01339403Results posted
• Evaluation of 3TC or FTC Mono-therapy Compared to Continuing HAART as a Bridging StrategyTerminatedNCT01338025Phase 4Results posted
• Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infectionCompletedNCT01328158Results posted
• A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.CompletedNCT01328041Phase 3Results posted
• Personalized Text Messages to Improve Antiretroviral Treatment (ART) Adherence in HIV+ Methamphetamine UsersCompletedNCT01317277Not applicableResults posted
• Interferon Alfa Sensitivity in HIV/HCV Persons Before and After HIV MedsCompletedNCT01285050Phase 4Results posted
• Combivir And Maraviroc In Antiretroviral Naive Subjects In RussiaCompletedNCT01275625Phase 4Results posted
• Naltrexone for Opioid Dependent Released Human Immunodeficiency Virus Positive (HIV+) Criminal Justice PopulationsCompletedNCT01246401Phase 1/2Results posted
• Post-Exposure Prophylaxis in Health Care WorkersCompletedNCT01234116Phase 4Results posted
• Dose-finding Study of GSK2248761 in Antiretroviral Therapy-Naive Subjects (SIGNET)TerminatedNCT01231555Phase 2Results posted
• A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive AdultsCompletedNCT01231516Phase 3Results posted
• Bone Loss and Immune Reconstitution in HIV/AIDS (BLIR-HIV)CompletedNCT01228318Phase 2Results posted
• Efficacy and Safety of GSK Biologicals HIV Vaccine in Antiretroviral Therapy (ART)-naïve HIV-1 Infected PersonsCompletedNCT01218113Phase 2Results posted
• A Study to Assess the Efficacy of Raltegravir (Isentress®), Administered in Combination With Other Antiretroviral Drugs as Treatment for Adults and Older Adults Infected With the Human Immunodeficiency Virus 1 (HIV-1)(MK-0518-145) (Wirksamkeit Von Isentress® Unter Praxisbedingungen)CompletedNCT01213316Results posted
• R5 Integrase Study in HIV-1 Naive PatientsCompletedNCT01204905Not applicableResults posted
• A Study of the Once Daily Combination of Etravirine and Darunavir/Ritonavir As Dual Therapy in Early Treatment-Experienced PatientsCompletedNCT01199939Phase 2Results posted
• Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV InfectionTerminatedNCT01199731Phase 2Results posted
• Raltegravir With Optimized Background Therapy (OBT) in Multiple Experienced HIV-infected PatientsCompletedNCT01190124Results posted
• A Controlled Trial to Evaluate the Effects of GanedenBC30 on the Immune SystemCompletedNCT01184456Phase 2Results posted
• HIV Rapid Testing & Counseling in Sexually Transmitted Disease (STD) Clinics in the U.S.CompletedNCT01154296Not applicableResults posted
• Long-term Effectiveness and Safety in Hepatitis-co-infected PatientsCompletedNCT01153269Results posted
• Treatment Options for Protease Inhibitor-exposed ChildrenCompletedNCT01146873Phase 3Results posted
• HIV-1 Peptide Immunisation of Individuals in West Africa to Prevent DiseaseCompletedNCT01141205Phase 1Results posted
• A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)CompletedNCT01102972Phase 4Results posted
• Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra TabletCompletedNCT01097655Results posted
• Study of Vitamin D and Effect on Heart Disease and Insulin ResistanceCompletedNCT01093417Phase 2Results posted
• Vitamin D Dose Finding StudyCompletedNCT01092338Phase 2Results posted
• Mesalamine to Reduce T Cell Activation in HIV InfectionCompletedNCT01090102Phase 4Results posted
• HIV and Fat AccumulationCompletedNCT01088295Phase 2Results posted
• Evaluation of Kaletra Therapy Over the Long-termCompletedNCT01083810Results posted
• Alcohol Pharmacotherapy for HIV+ PrisonersCompletedNCT01077310Not applicableResults posted
• Special Investigation of Kaletra in Pregnant WomenCompletedNCT01076985Results posted
• Drug Use Investigation of KaletraCompletedNCT01076972Results posted
• Kaletra in Combination With Antiretroviral AgentsCompletedNCT01076179Results posted
• Kaletra: Therapy With Double Protease InhibitorsCompletedNCT01075191Results posted
• Cryptococcal Optimal ART Timing TrialCompletedNCT01075152Phase 4Results posted
• Fosamprenavir in Pts With Hepatic ImpairmentCompletedNCT01054586Results posted
• Effect of Seminal Fluid on the Colon Wall; Implications for HIV TransmissionCompletedNCT01053741Not applicableResults posted
• Pilot Study of Raltegravir Switch to Resolve Tenofovir Induced ProteinuriaCompletedNCT01044771Not applicableResults posted
• Triomune Bioequivalence With InnovatorsCompletedNCT01025830Phase 4Results posted
• HIV Acquired Lipodystrophy (HAL) Classification, Measurement and Fat Response to Thiazolidinedione (TZD) (Pioglitazone)CompletedNCT01023620Not applicableResults posted
• H1N1 Vaccine at Two Dose Levels in HIV Positive AdultsCompletedNCT00992433Phase 2Results posted
• Study of Niacin on Endothelial Function in HIV-infected Subjects With Low High Density Lipoprotein Cholesterol LevelsCompletedNCT00986986Not applicableResults posted
• Pharmacokinetics of Lopinavir/Ritonavir at Three Different Doses.CompletedNCT00985543Phase 1Results posted
• Evaluation of the Immune Response of a HIV Candidate Vaccine After Administration of One Chloroquine DoseCompletedNCT00972725Phase 2Results posted
• Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPSCompletedNCT00963235Phase 3Results posted
• Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in HIV-Infected Subjects 6 Years of Age or Older Who Are Naive to Pneumococcal VaccineCompletedNCT00962780Phase 3Results posted
• A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive SubjectsCompletedNCT00951015Phase 2Results posted
• A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to RaltegravirCompletedNCT00950859Phase 2Results posted
• Safety and Tolerability Study to Evaluate Lower Dose of GSK2248761 in Antiretroviral Treatment-Naive HIV-1 Infected Adults.CompletedNCT00945282Phase 2Results posted
• Evaluation of Diagnostic HIV Ag/Ab Combo AssayCompletedNCT00933933Phase 3Results posted
• BATAR: Individuals Currently Taking Boosted Atazanavir as Part of an HIV Treatment Regimen Will be Evaluated to See if Substituting Raltegravir for Nucleoside Transcriptase Inhibitors Will be Safe and Well Tolerated.CompletedNCT00931801Phase 4Results posted
• A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line RegimenCompletedNCT00931463Phase 4Results posted

← Acquired Immunodeficiency Syndrome overview